Published in Medical Letter on the CDC and FDA, October 15th, 2006
Statistical significance was achieved for the primary clinical endpoints of incidence of patients achieving 100% wound closure as well as acceleration of wound closure with the OrCel-treated patients as early as the third week and was maintained from week five through week eleven using the statistical approach required and approved by the U.S. Food and Drug Administration...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA